Private Wealth Partners LLC Purchases 2,728 Shares of Johnson & Johnson (NYSE:JNJ)

Private Wealth Partners LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,155 shares of the company’s stock after purchasing an additional 2,728 shares during the quarter. Johnson & Johnson comprises 0.9% of Private Wealth Partners LLC’s holdings, making the stock its 28th largest holding. Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $12,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in JNJ. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $31,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $32,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Up 1.7 %

Shares of NYSE JNJ opened at $162.35 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a 50 day moving average price of $148.93 and a two-hundred day moving average price of $155.88. The stock has a market cap of $390.87 billion, a P/E ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.29 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.